Feasibility of two schedules of weekly paclitaxel in HER2-negative early breast cancer in a Brazilian community setting
Background Weekly paclitaxel has been shown more effective and less toxic than the conventional three-weekly administration. The GEICAM 9906 demonstrated effectiveness and safety of a dose-dense schedule of 100 mg/m 2 of paclitaxel given over 8 weeks (w). This schedule has been adopted at our instit...
Gespeichert in:
| Veröffentlicht in: | Breast cancer (Tokyo, Japan) Japan), 2016-03, Vol.23 (2), p.261-265 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 265 |
|---|---|
| container_issue | 2 |
| container_start_page | 261 |
| container_title | Breast cancer (Tokyo, Japan) |
| container_volume | 23 |
| creator | Santana, Iuri A. Oliveira, Julia Andrade da Silva Lima, Julianne Maria Testa, Laura Piato, José Roberto M. Hoff, Paulo M. Mano, Max S. |
| description | Background
Weekly paclitaxel has been shown more effective and less toxic than the conventional three-weekly administration. The GEICAM 9906 demonstrated effectiveness and safety of a dose-dense schedule of 100 mg/m
2
of paclitaxel given over 8 weeks (w). This schedule has been adopted at our institution in 2009 for HER2-negative disease, and herein, we present the first off-trial experience and compare its safety profile with that of a historical cohort of patients treated with the conventional 80 mg/m
2
over 12 w schedule.
Methods
Retrospective single-center chart review of patients with locally advanced breast cancer treated with (neo)adjuvant paclitaxel-based therapy from 2008 to 2012 with (1) 80 mg/m
2
for 12 w or (2) 100 mg/m
2
for 8 w. Adverse events were graded according to common terminology criteria for adverse events (CTCAE) 4.0.
Results
A total of 326 patients were analyzed. Median age was 52 (±10.9). Seventy and 256 patients received schedule (1) and (2), respectively. No significant difference was observed in the incidence of grade (G) 3/4 toxicity: pneumonitis (2.8 vs 0.3 %
p
= 0.097); neuropathy (2.8 vs 0.7 %
p
= 0.303); hand–foot syndrome (1.4 vs 0.3 %
p
= 0.538); anemia (0 vs 0.6 %
p
= 0.624); and neutropenia (5.7 vs 6.2 %
p
= 0.408). Also, no significant difference was seen when comparing all grades toxicity. Schedule (2) had higher dose intensity: 97.72 vs 77.07 mg/m
2
per week (
p
|
| doi_str_mv | 10.1007/s12282-014-0564-9 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_1770216709</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A712277129</galeid><sourcerecordid>A712277129</sourcerecordid><originalsourceid>FETCH-LOGICAL-c505t-526178ca3d1cfaf85c1f83c8bf7c2e9b83527cef3bec96269468f8ff5b6db0de3</originalsourceid><addsrcrecordid>eNp9kU9rFTEUxYMotlY_gBsJuHGTmj8zSWZZS2uFgiC6DpnMzTN1JnkmM30-P70ZpgqCSCC53PzOSbgHoZeMnjNK1dvCONecUNYQ2sqGdI_QKdOakoYL8bjWoqFEaqlP0LNS7ihthKLyKTrhLRcNE-oUHa7BltCHMcxHnDyeDwkX9xWGZYSyNg4A38Yj3ltXEfsDRhwivrn6xEmEnZ3DPWCwuRJ9rk4zdjY6yCtk8btsf1ZnG7FL07TE9Y0C8xzi7jl64u1Y4MXDeYa-XF99vrwhtx_ff7i8uCWupe1MWi6Z0s6KgTlvvW4d81o43XvlOHS9Fi1XDrzowXWSy66R2mvv214OPR1AnKE3m-8-p-8LlNlMoTgYRxshLcUwpShnUtGuoq83dGdHMCH6NGfrVtxcqDppVbeVOv8HVdcAU3Apgg-1_5eAbQKXUykZvNnnMNl8NIyaNUazxWhqjGaN0ayaVw-_XvoJhj-K37lVgG9AqVdxB9ncpSXHOsn_uP4ClVCoYw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1770216709</pqid></control><display><type>article</type><title>Feasibility of two schedules of weekly paclitaxel in HER2-negative early breast cancer in a Brazilian community setting</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Santana, Iuri A. ; Oliveira, Julia Andrade ; da Silva Lima, Julianne Maria ; Testa, Laura ; Piato, José Roberto M. ; Hoff, Paulo M. ; Mano, Max S.</creator><creatorcontrib>Santana, Iuri A. ; Oliveira, Julia Andrade ; da Silva Lima, Julianne Maria ; Testa, Laura ; Piato, José Roberto M. ; Hoff, Paulo M. ; Mano, Max S.</creatorcontrib><description>Background
Weekly paclitaxel has been shown more effective and less toxic than the conventional three-weekly administration. The GEICAM 9906 demonstrated effectiveness and safety of a dose-dense schedule of 100 mg/m
2
of paclitaxel given over 8 weeks (w). This schedule has been adopted at our institution in 2009 for HER2-negative disease, and herein, we present the first off-trial experience and compare its safety profile with that of a historical cohort of patients treated with the conventional 80 mg/m
2
over 12 w schedule.
Methods
Retrospective single-center chart review of patients with locally advanced breast cancer treated with (neo)adjuvant paclitaxel-based therapy from 2008 to 2012 with (1) 80 mg/m
2
for 12 w or (2) 100 mg/m
2
for 8 w. Adverse events were graded according to common terminology criteria for adverse events (CTCAE) 4.0.
Results
A total of 326 patients were analyzed. Median age was 52 (±10.9). Seventy and 256 patients received schedule (1) and (2), respectively. No significant difference was observed in the incidence of grade (G) 3/4 toxicity: pneumonitis (2.8 vs 0.3 %
p
= 0.097); neuropathy (2.8 vs 0.7 %
p
= 0.303); hand–foot syndrome (1.4 vs 0.3 %
p
= 0.538); anemia (0 vs 0.6 %
p
= 0.624); and neutropenia (5.7 vs 6.2 %
p
= 0.408). Also, no significant difference was seen when comparing all grades toxicity. Schedule (2) had higher dose intensity: 97.72 vs 77.07 mg/m
2
per week (
p
< 0.0001).
Conclusions
Weekly paclitaxel given according to GEICAM 9906 is pragmatic and well tolerated, with safety profile consistent with the conventional schedule. In addition to being convenient to patients, it may also be cost-effective because of a lower number of clinic visits and infusions.</description><identifier>ISSN: 1340-6868</identifier><identifier>EISSN: 1880-4233</identifier><identifier>DOI: 10.1007/s12282-014-0564-9</identifier><identifier>PMID: 25234137</identifier><language>eng</language><publisher>Tokyo: Springer Japan</publisher><subject>Adjuvant treatment ; Adult ; Aged ; Antineoplastic Agents, Phytogenic - therapeutic use ; Biomarkers, Tumor - metabolism ; Brazil ; Breast cancer ; Breast Neoplasms - drug therapy ; Breast Neoplasms - pathology ; Cancer ; Cancer Research ; Care and treatment ; Drug Administration Schedule ; Feasibility Studies ; Female ; Follow-Up Studies ; Humans ; Immunoenzyme Techniques ; Medicine ; Medicine & Public Health ; Middle Aged ; Neoplasm Staging ; Oncology ; Original Article ; Paclitaxel - therapeutic use ; Prognosis ; Receptor, ErbB-2 - metabolism ; Receptors, Estrogen - metabolism ; Receptors, Progesterone - metabolism ; Retrospective Studies ; Surgery ; Surgical Oncology ; Survival Rate</subject><ispartof>Breast cancer (Tokyo, Japan), 2016-03, Vol.23 (2), p.261-265</ispartof><rights>The Japanese Breast Cancer Society 2014</rights><rights>COPYRIGHT 2016 Springer</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c505t-526178ca3d1cfaf85c1f83c8bf7c2e9b83527cef3bec96269468f8ff5b6db0de3</citedby><cites>FETCH-LOGICAL-c505t-526178ca3d1cfaf85c1f83c8bf7c2e9b83527cef3bec96269468f8ff5b6db0de3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12282-014-0564-9$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12282-014-0564-9$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,777,781,27905,27906,41469,42538,51300</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25234137$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Santana, Iuri A.</creatorcontrib><creatorcontrib>Oliveira, Julia Andrade</creatorcontrib><creatorcontrib>da Silva Lima, Julianne Maria</creatorcontrib><creatorcontrib>Testa, Laura</creatorcontrib><creatorcontrib>Piato, José Roberto M.</creatorcontrib><creatorcontrib>Hoff, Paulo M.</creatorcontrib><creatorcontrib>Mano, Max S.</creatorcontrib><title>Feasibility of two schedules of weekly paclitaxel in HER2-negative early breast cancer in a Brazilian community setting</title><title>Breast cancer (Tokyo, Japan)</title><addtitle>Breast Cancer</addtitle><addtitle>Breast Cancer</addtitle><description>Background
Weekly paclitaxel has been shown more effective and less toxic than the conventional three-weekly administration. The GEICAM 9906 demonstrated effectiveness and safety of a dose-dense schedule of 100 mg/m
2
of paclitaxel given over 8 weeks (w). This schedule has been adopted at our institution in 2009 for HER2-negative disease, and herein, we present the first off-trial experience and compare its safety profile with that of a historical cohort of patients treated with the conventional 80 mg/m
2
over 12 w schedule.
Methods
Retrospective single-center chart review of patients with locally advanced breast cancer treated with (neo)adjuvant paclitaxel-based therapy from 2008 to 2012 with (1) 80 mg/m
2
for 12 w or (2) 100 mg/m
2
for 8 w. Adverse events were graded according to common terminology criteria for adverse events (CTCAE) 4.0.
Results
A total of 326 patients were analyzed. Median age was 52 (±10.9). Seventy and 256 patients received schedule (1) and (2), respectively. No significant difference was observed in the incidence of grade (G) 3/4 toxicity: pneumonitis (2.8 vs 0.3 %
p
= 0.097); neuropathy (2.8 vs 0.7 %
p
= 0.303); hand–foot syndrome (1.4 vs 0.3 %
p
= 0.538); anemia (0 vs 0.6 %
p
= 0.624); and neutropenia (5.7 vs 6.2 %
p
= 0.408). Also, no significant difference was seen when comparing all grades toxicity. Schedule (2) had higher dose intensity: 97.72 vs 77.07 mg/m
2
per week (
p
< 0.0001).
Conclusions
Weekly paclitaxel given according to GEICAM 9906 is pragmatic and well tolerated, with safety profile consistent with the conventional schedule. In addition to being convenient to patients, it may also be cost-effective because of a lower number of clinic visits and infusions.</description><subject>Adjuvant treatment</subject><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Agents, Phytogenic - therapeutic use</subject><subject>Biomarkers, Tumor - metabolism</subject><subject>Brazil</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - pathology</subject><subject>Cancer</subject><subject>Cancer Research</subject><subject>Care and treatment</subject><subject>Drug Administration Schedule</subject><subject>Feasibility Studies</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Immunoenzyme Techniques</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Neoplasm Staging</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Paclitaxel - therapeutic use</subject><subject>Prognosis</subject><subject>Receptor, ErbB-2 - metabolism</subject><subject>Receptors, Estrogen - metabolism</subject><subject>Receptors, Progesterone - metabolism</subject><subject>Retrospective Studies</subject><subject>Surgery</subject><subject>Surgical Oncology</subject><subject>Survival Rate</subject><issn>1340-6868</issn><issn>1880-4233</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU9rFTEUxYMotlY_gBsJuHGTmj8zSWZZS2uFgiC6DpnMzTN1JnkmM30-P70ZpgqCSCC53PzOSbgHoZeMnjNK1dvCONecUNYQ2sqGdI_QKdOakoYL8bjWoqFEaqlP0LNS7ihthKLyKTrhLRcNE-oUHa7BltCHMcxHnDyeDwkX9xWGZYSyNg4A38Yj3ltXEfsDRhwivrn6xEmEnZ3DPWCwuRJ9rk4zdjY6yCtk8btsf1ZnG7FL07TE9Y0C8xzi7jl64u1Y4MXDeYa-XF99vrwhtx_ff7i8uCWupe1MWi6Z0s6KgTlvvW4d81o43XvlOHS9Fi1XDrzowXWSy66R2mvv214OPR1AnKE3m-8-p-8LlNlMoTgYRxshLcUwpShnUtGuoq83dGdHMCH6NGfrVtxcqDppVbeVOv8HVdcAU3Apgg-1_5eAbQKXUykZvNnnMNl8NIyaNUazxWhqjGaN0ayaVw-_XvoJhj-K37lVgG9AqVdxB9ncpSXHOsn_uP4ClVCoYw</recordid><startdate>20160301</startdate><enddate>20160301</enddate><creator>Santana, Iuri A.</creator><creator>Oliveira, Julia Andrade</creator><creator>da Silva Lima, Julianne Maria</creator><creator>Testa, Laura</creator><creator>Piato, José Roberto M.</creator><creator>Hoff, Paulo M.</creator><creator>Mano, Max S.</creator><general>Springer Japan</general><general>Springer</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20160301</creationdate><title>Feasibility of two schedules of weekly paclitaxel in HER2-negative early breast cancer in a Brazilian community setting</title><author>Santana, Iuri A. ; Oliveira, Julia Andrade ; da Silva Lima, Julianne Maria ; Testa, Laura ; Piato, José Roberto M. ; Hoff, Paulo M. ; Mano, Max S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c505t-526178ca3d1cfaf85c1f83c8bf7c2e9b83527cef3bec96269468f8ff5b6db0de3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adjuvant treatment</topic><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Agents, Phytogenic - therapeutic use</topic><topic>Biomarkers, Tumor - metabolism</topic><topic>Brazil</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - pathology</topic><topic>Cancer</topic><topic>Cancer Research</topic><topic>Care and treatment</topic><topic>Drug Administration Schedule</topic><topic>Feasibility Studies</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Immunoenzyme Techniques</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Neoplasm Staging</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Paclitaxel - therapeutic use</topic><topic>Prognosis</topic><topic>Receptor, ErbB-2 - metabolism</topic><topic>Receptors, Estrogen - metabolism</topic><topic>Receptors, Progesterone - metabolism</topic><topic>Retrospective Studies</topic><topic>Surgery</topic><topic>Surgical Oncology</topic><topic>Survival Rate</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Santana, Iuri A.</creatorcontrib><creatorcontrib>Oliveira, Julia Andrade</creatorcontrib><creatorcontrib>da Silva Lima, Julianne Maria</creatorcontrib><creatorcontrib>Testa, Laura</creatorcontrib><creatorcontrib>Piato, José Roberto M.</creatorcontrib><creatorcontrib>Hoff, Paulo M.</creatorcontrib><creatorcontrib>Mano, Max S.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Breast cancer (Tokyo, Japan)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Santana, Iuri A.</au><au>Oliveira, Julia Andrade</au><au>da Silva Lima, Julianne Maria</au><au>Testa, Laura</au><au>Piato, José Roberto M.</au><au>Hoff, Paulo M.</au><au>Mano, Max S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Feasibility of two schedules of weekly paclitaxel in HER2-negative early breast cancer in a Brazilian community setting</atitle><jtitle>Breast cancer (Tokyo, Japan)</jtitle><stitle>Breast Cancer</stitle><addtitle>Breast Cancer</addtitle><date>2016-03-01</date><risdate>2016</risdate><volume>23</volume><issue>2</issue><spage>261</spage><epage>265</epage><pages>261-265</pages><issn>1340-6868</issn><eissn>1880-4233</eissn><abstract>Background
Weekly paclitaxel has been shown more effective and less toxic than the conventional three-weekly administration. The GEICAM 9906 demonstrated effectiveness and safety of a dose-dense schedule of 100 mg/m
2
of paclitaxel given over 8 weeks (w). This schedule has been adopted at our institution in 2009 for HER2-negative disease, and herein, we present the first off-trial experience and compare its safety profile with that of a historical cohort of patients treated with the conventional 80 mg/m
2
over 12 w schedule.
Methods
Retrospective single-center chart review of patients with locally advanced breast cancer treated with (neo)adjuvant paclitaxel-based therapy from 2008 to 2012 with (1) 80 mg/m
2
for 12 w or (2) 100 mg/m
2
for 8 w. Adverse events were graded according to common terminology criteria for adverse events (CTCAE) 4.0.
Results
A total of 326 patients were analyzed. Median age was 52 (±10.9). Seventy and 256 patients received schedule (1) and (2), respectively. No significant difference was observed in the incidence of grade (G) 3/4 toxicity: pneumonitis (2.8 vs 0.3 %
p
= 0.097); neuropathy (2.8 vs 0.7 %
p
= 0.303); hand–foot syndrome (1.4 vs 0.3 %
p
= 0.538); anemia (0 vs 0.6 %
p
= 0.624); and neutropenia (5.7 vs 6.2 %
p
= 0.408). Also, no significant difference was seen when comparing all grades toxicity. Schedule (2) had higher dose intensity: 97.72 vs 77.07 mg/m
2
per week (
p
< 0.0001).
Conclusions
Weekly paclitaxel given according to GEICAM 9906 is pragmatic and well tolerated, with safety profile consistent with the conventional schedule. In addition to being convenient to patients, it may also be cost-effective because of a lower number of clinic visits and infusions.</abstract><cop>Tokyo</cop><pub>Springer Japan</pub><pmid>25234137</pmid><doi>10.1007/s12282-014-0564-9</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1340-6868 |
| ispartof | Breast cancer (Tokyo, Japan), 2016-03, Vol.23 (2), p.261-265 |
| issn | 1340-6868 1880-4233 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1770216709 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Adjuvant treatment Adult Aged Antineoplastic Agents, Phytogenic - therapeutic use Biomarkers, Tumor - metabolism Brazil Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - pathology Cancer Cancer Research Care and treatment Drug Administration Schedule Feasibility Studies Female Follow-Up Studies Humans Immunoenzyme Techniques Medicine Medicine & Public Health Middle Aged Neoplasm Staging Oncology Original Article Paclitaxel - therapeutic use Prognosis Receptor, ErbB-2 - metabolism Receptors, Estrogen - metabolism Receptors, Progesterone - metabolism Retrospective Studies Surgery Surgical Oncology Survival Rate |
| title | Feasibility of two schedules of weekly paclitaxel in HER2-negative early breast cancer in a Brazilian community setting |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T18%3A42%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Feasibility%20of%20two%20schedules%20of%20weekly%20paclitaxel%20in%20HER2-negative%20early%20breast%20cancer%20in%20a%20Brazilian%20community%20setting&rft.jtitle=Breast%20cancer%20(Tokyo,%20Japan)&rft.au=Santana,%20Iuri%20A.&rft.date=2016-03-01&rft.volume=23&rft.issue=2&rft.spage=261&rft.epage=265&rft.pages=261-265&rft.issn=1340-6868&rft.eissn=1880-4233&rft_id=info:doi/10.1007/s12282-014-0564-9&rft_dat=%3Cgale_proqu%3EA712277129%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1770216709&rft_id=info:pmid/25234137&rft_galeid=A712277129&rfr_iscdi=true |